Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dermatophagoides pteronyssinus
- Development stage
- Approved
- Lead developer
- ALK Abelló
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Sublingual, Intradermal, Intranasal, Inhalation
01
Overview
Dermatophagoides pteronyssinus allergen extract is a biological product derived from the house dust mite species of the same name, used primarily for the diagnosis and treatment of IgE-mediated allergic diseases such as allergic rhinitis, allergic conjunctivitis, and allergic asthma. As a diagnostic agent, it is employed in skin prick testing and provocation tests (nasal or bronchial) to identify hypersensitivity. As a therapeutic agent, it is used in allergen-specific immunotherapy (AIT), administered either subcutaneously (SCIT) or sublingually (SLIT). The mechanism of action involves modulating the immune system to induce long-term tolerance, typically characterized by a shift from a Th2-biased allergic response to a Th1/Treg-mediated tolerant response. This process includes the induction of regulatory T-cells (Tregs), increased production of the anti-inflammatory cytokine IL-10, and the generation of allergen-specific IgG4 antibodies that act as blocking antibodies to prevent IgE-mediated mast cell and basophil degranulation.
- Brand names
- Alutard SQAquagenGreer Standardized Mite Extract
- Other names
- Der phouse dust mite extractDermatophagoides pteronyssinus allergen extractD. pteronyssinus
02
Targets
BCR (Immunoglobulin G B Cell Receptor)PAR2 (Protease-activated receptor 2)γδ TCR (T-cell receptor)A. annua-specific IgE (Artemisia annua-specific immunoglobulin E)IL10 (Interleukin-10)
Beyond the preview
Go deeper on dermatophagoides pteronyssinus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dermatophagoides pteronyssinus.